

*In the Claims:*

Please amend the above-identified application as set forth below.

1. (Currently Amended) A method of inducing pancreatic hormone expression in the liver of a mammal, wherein said pancreatic hormone is selected from the group consisting of insulin, somatostatin, and glucagon, said method comprising administering to a mammal an adenoviral particle comprising an adenovirus vector comprising a cytomegalovirus (CMV) promoter operably linked to a nucleic acid encoding a pancreatic and duodenal homobox 1 (PDX-1) polypeptide in an amount sufficient to induce said pancreatic hormone expression in said liver in said mammal.
10. (Previously Amended) The method of claim 1, wherein administering said vector increases hepatic insulin levels in said mammal.
11. (Previously Amended) The method of claim 1, wherein administering said vector increases serum insulin levels in said mammal.
12. (Previously Amended) The method of claim 1, wherein the mammal is a rodent or human.
13. (Previously Amended) The method of claim 1, wherein the mammal is further administered a transfection agent.
15. (Previously Amended) The method of claim 1, wherein the administering is by a route selected from the group consisting of intraperitoneal, subcutaneous, nasal, intravenous, oral and transdermal delivery.
29. (Currently Amended) A method of inducing a pancreatic islet gene expression profile in a liver cell of a subject, said method comprising administering to a subject an adenoviral particle comprising an adenovirus vector comprising a cytomegalovirus (CMV) promoter operably linked to a nucleic acid encoding a pancreatic and duodenal homobox 1 (PDX-1) polypeptide in an amount sufficient to induce said pancreatic islet gene expression in said liver cell in said subject.

30. (Original) The method of claim 29, wherein said pancreatic islet gene is insulin.
31. (Currently Cancelled)
33. (Currently Amended) A method of inducing insulin expression in the liver of a mammal, said method comprising administering to a mammal an adenoviral particle comprising an adenovirus vector comprising a cytomegalovirus (CMV) promoter operably linked to a nucleic acid encoding a pancreatic and duodenal homobox 1 (PDX-1) polypeptide in an amount sufficient to induce said insulin expression in said liver of said mammal.
34. (Currently Amended) A method of inducing glucagon expression in the liver of a mammal, said method comprising administering to a mammal an adenoviral particle comprising an adenovirus vector comprising a cytomegalovirus (CMV) promoter operably linked to a nucleic acid encoding a pancreatic and duodenal homobox 1 (PDX-1) polypeptide in an amount sufficient to induce said glucagon expression in said liver of said mammal.
35. (Currently Amended) A method of inducing somatostatin expression in the liver of a mammal, said method comprising administering to a mammal an adenoviral particle comprising an adenovirus vector comprising a cytomegalovirus (CMV) promoter operably linked to a nucleic acid encoding a pancreatic and duodenal homobox 1 (PDX-1) polypeptide in an amount sufficient to induce said somatostatin expression in said liver of said mammal.
36. (Currently Amended) A method of inducing prohormone convertase 1/3 (PC 1/3) expression in the liver of a mammal, said method comprising administering to a mammal an adenoviral particle comprising an adenovirus vector comprising a cytomegalovirus (CMV) promoter operably linked to a nucleic acid encoding a pancreatic and duodenal homobox 1 (PDX-1) polypeptide in an amount sufficient to induce said PC 1/3 expression in said liver of said mammal.

37. (Previously Added) A method of inducing pancreatic hormone expression in a liver cell, wherein said pancreatic hormone is selected from the group consisting of insulin, somatostatin, and glucagon, said method comprising contacting said cell with an adenovirus vector comprising a cytomegalovirus (CMV) promoter operably linked to a nucleic acid encoding a pancreatic and duodenal homobox 1 (PDX-1) polypeptide, thereby inducing said pancreatic hormone expression in said liver cell.
38. (Previously Added) A method of inducing insulin expression in a liver cell, said method comprising contacting said cell with an adenovirus vector comprising a cytomegalovirus (CMV) promoter operably linked to a nucleic acid encoding a pancreatic and duodenal homobox 1 (PDX-1) polypeptide, thereby inducing said insulin expression in said liver cell.
39. (Previously Added) A method of inducing somatostatin expression in a liver cell, said method comprising contacting said cell with an adenovirus vector comprising a cytomegalovirus (CMV) promoter operably linked to a nucleic acid encoding a pancreatic and duodenal homobox 1 (PDX-1) polypeptide, thereby inducing said somatostatin expression in said liver cell.
40. (Previously Added) A method of inducing glucagon expression in a liver cell, said method comprising contacting said cell with an adenovirus vector comprising a cytomegalovirus (CMV) promoter operably linked to a nucleic acid encoding a pancreatic and duodenal homobox 1 (PDX-1) polypeptide, thereby inducing said glucagon expression in said liver cell.
41. (Previously Added) A method of inducing prohormone convertase 1/3 (PC 1/3) expression in a liver cell, said method comprising contacting said cell with an adenovirus vector comprising a cytomegalovirus (CMV) promoter operably linked to a nucleic acid encoding a pancreatic and duodenal homobox 1 (PDX-1) polypeptide, thereby inducing said PC 1/3 expression in said liver cell.

42. (Previously Added) A composition comprising an adenovirus vector comprising a cytomegalovirus (CMV) promoter operably linked to a nucleic acid encoding a pancreatic and duodenal homobox 1 (PDX-1) polypeptide, and a carrier.
43. (Currently Added) A method of inducing pancreatic hormone expression in a skin cell, wherein said pancreatic hormone is selected from the group consisting of insulin, somatostatin, and glucagon, said method comprising introducing to said cell a composition comprising an adenovirus vector comprising a cytomegalovirus (CMV) promoter operably linked to a nucleic acid encoding a pancreatic and duodenal homobox 1 (PDX-1) polypeptide, thereby inducing said pancreatic hormone expression in said skin cell.
44. (Currently Added) A method of inducing insulin expression in a skin cell, said method comprising introducing to said cell a composition comprising an adenovirus vector comprising a cytomegalovirus (CMV) promoter operably linked to a nucleic acid encoding a pancreatic and duodenal homobox 1 (PDX-1) polypeptide, thereby inducing said insulin expression in said skin cell.
45. (Currently Added) A method of inducing somatostatin expression in a skin cell, said method comprising introducing to said cell a composition comprising an adenovirus vector comprising a cytomegalovirus (CMV) promoter operably linked to a nucleic acid encoding a pancreatic and duodenal homobox 1 (PDX-1) polypeptide, thereby inducing said somatostatin expression in said skin cell.
46. (Currently Added) A method of inducing glucagon expression in a skin cell, said method comprising introducing to said cell a composition comprising an adenovirus vector comprising a cytomegalovirus (CMV) promoter operably linked to a nucleic acid encoding a pancreatic and duodenal homobox 1 (PDX-1) polypeptide, thereby inducing said glucagon expression in said skin cell.
47. (Currently Added) A method of inducing prohormone convertase 1/3 (PC 1/3) expression in a skin cell, said method comprising introducing to said cell a composition

comprising an adenovirus vector comprising a cytomegalovirus (CMV) promoter operably linked to a nucleic acid encoding a pancreatic and duodenal homobox 1 (PDX-1) polypeptide, thereby inducing said PC 1/3 expression in said skin cell.

48. (Currently Added) A method of inducing endogenous PDX-1 expression in a cell, said method comprising introducing to said cell a composition comprising an adenovirus vector comprising a nucleic acid encoding a pancreatic and duodenal homobox 1 (PDX-1) polypeptide, thereby inducing said endogenous PDX-1 expression in said cell.
49. (Currently Added) The method of claim 48, wherein said nucleic acid is operably linked to a promoter.
50. (Currently Added) The method of claim 48, wherein said promoter is a cytomegalovirus (CMV) promoter.